Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical devic⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$2.49
Price+0.40%
$0.01
$134.348m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$2.944m
-
1y CAGR-
3y CAGR-
5y CAGR-$69.699m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.82
-
1y CAGR-
3y CAGR-
5y CAGR$295k
$42.825m
Assets$42.530m
Liabilities$1.970m
Debt4.6%
-
Debt to EBITDA-$59.701m
-
1y CAGR-
3y CAGR-
5y CAGR